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of follow-up. According to wPCDAI, 29.0% of patients were in 
clinical remission, whereas 39%, 13%, and 19% had mild, moder-
ate, and severe disease, respectively. IMPACT-III total score had a 
poor but significant correlation with degree of mucosal inflamma-
tion judged by the SES-CD (r =  -0.285, p < 0.0001). Correlation 
was strong with clinical activity judged by wPCDAI (r  =  -0.550, 
p < 0.0001). Patients with higher disease activity had lower total 
IMPACT-III score, as did the 4 domains (wellbeing, emotional func-
tioning, social functioning, and body image, Table I). Differences 
across wPCDAI groups were higher for wellbeing and lower for 
body-image domains (Figure 1).
Patients with perianal disease had lower wellbeing (p = 0.026) and 
body image (p = 0.004) domain scores. Steroid treatment was asso-
ciated more with lower emotional functioning score than enteral 
nutrition was (p = 0.028).
Conclusions: In this ImageKids cohort, HRQOL was lower in 
patients with higher disease activity and in those with perianal dis-
ease. An awareness of which domains within IMPACT may be dif-
ferentially affected by various therapies or disease characteristics 
could help the clinician by focusing interventions (ie, psychological) 
to address these areas of concern.
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Background: The Harvey–Bradshaw Index (HBI) is frequently used 
in daily clinical practice to assess disease activity in patients with 
Crohn’s disease (CD). The goal of this study was to evaluate thera-
peutic response and predictors of response in CD patients treated 
with adalimumab (ADA) for 12 months during routine clinical care.
Methods: We analysed data from a large German multicentre obser-
vational study of patients with active CD who initiated ADA therapy 
during routine clinical care. Key outcome measures included mean 
HBI (scale of 0 to 16; lower scores indicate better health status) 
and the proportion of patients achieving HBI remission (≤ 4) over 
12 months. Stepwise regression analyses were performed to assess 
the effect of clinically important demographic and disease variables, 
including smoking status, age, sex, duration of illness, disease sever-
ity, and CD-related surgeries, on therapeutic response as assessed by 
change in the HBI from baseline (BL) to month 12. T-tests were used 
to assess the change in HBI from BL month 12.
Results: Of 1 863 patients in the full analysis set, 611 patients had 
available data on HBI at BL and mo 12. The mean age of the patients 
at BL (before initiation of ADA) was 37.4 ± 12.7 years; the age at 
first diagnosis was 27.7 ± 11.5 years; and mean disease duration was 
9.7 ± 8.3 years. The majority of patients (63.5%) were female. At BL, 
the mean HBI was 9.9 ± 5.1. After initiation of ADA treatment, this 
value fell to 4.3 ± 4.3 at month 3, 4.0 ± 4.2 at month 6, and 4.2 ± 4.3 
at month 12 (p < 0.001 for change in HBI from BL to month 12). 
The remission rate (proportion of patients with HBI ≤ 4) was 58.3% 
at month 3, 62.5% at month 6, and 62.8% at month 12. Significant 
negative predictors for improvement of HBI from BL to month 12 
were smoking, older age, and CD-related surgeries before initiation 
of ADA therapy. Subgroup analyses of HBI values for these predic-
tors are shown in the Table. A high baseline HBI value was also a 
negative predictor.
Conclusions: HBI improvement was observed by month 3 after ini-
tiation of ADA treatment, and this effect was maintained through-
out the 12-month observation period. Over 60% of ADA-treated 
patients achieved HBI defined remission by month 12. Smoking, 
CD-related surgeries before ADA treatment, and older age at BL 
reduced the response to therapy.
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Background: Systematic endoscopic evaluation of an ileo-anal pouch 
is important in assessing pouch dysfunction. Endoscopists are often 
inexperienced in pouchoscopy and tend to report abnormal findings 
only. However, a systematic approach is important and normal find-
ings may be equally important in the diagnostic or therapeutic pro-
cess.The aims of this study were to develop a standardised reporting 
template and review the status of pouchoscopy reports. Secondary 
aims were to implement this template to standardise pouchoscopy 
reports and see if the standard of documentation improved as a result.
Methods: A group of ileo-anal pouch experts (n = 4) compiled a list 
of items that should be documented at pouchoscopy. Reports over a 
period of 3 months were reviewed for their completeness compared 
with the template. The template was then introduced for 3 months, 
and reports obtained during that time were analysed.
Results: In total, 121 reports, generated between March 2015 and 
June 2015, were reviewed. The anus and peri-anal area was specifi-
cally described in 12% of the reports, rectal cuff in 55%, pouch-anal 
anastomosis in 37%, pouch body in 98%, pouch inlet in 13%, and 
pre-pouch ileum in 61%. From August 2015 until November 2015, 
the template was introduced, and 63 reports were obtained. There 
was a significant improvement in documentation of the anus and 
peri-anal area (to 51%, p < 0.0001), rectal cuff (to 75%, p = 0.0104), 
pouch-anal anastomosis (to 67%, p = 0.0002), and pouch inlet (to 
41%, p < 0.0001). Overall, there was a significant improvement in 
documentation 15 out of 22 features.
Sub-analysis to review the improvement of documentation of 
absence of inflammation, showed a significant improvement in all 3 
anatomical sites (rectal cuff p = 0.0012, pouch body p = 0.0004, and 
pre-pouch ileum p < 0.0001).
In both retrospective and prospective analysis, findings concern-
ing the rectal cuff were reported by endoscopy nurses more often 
than by consultants (p  < 0.0001 and p  = 0.0008), and the pouch 
inlet was documented more often by consultants (p < 0.0087 and 
p = 0.0003). By introducing the template, documentation by consult-
ants improved for the anus and peri-anal area (p = 0.0333), pouch 
inlet (p < 0.0001), and pre-pouch ileum (p = 0.0409). Documentation 
by endoscopy nurses improved for the anus and peri-anal area 
(p < 0.0001), as well as the pouch-anal anastomosis (p < 0.0001), 
pouch inlet (p = 0.0046), and pre-pouch ileum (p = 0.0152).
Conclusions: The introduction of the template improved documen-
tation of pouchoscopy significantly, including the documentation of 
normal findings. The template universally improved documentation 
across different types of endoscopists.
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